BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 29, 2021
View Archived Issues
Intratumoral cytokine-encoding mRNA mixture induces antitumor immunity in tumor models
Read More
BP-1200_002, a novel anti-CD73 antibody that improves efficacy of cancer immunotherapy
Read More
Development of NTC-001, a first-in-class humanized antibody targeting CXCL1
Read More
New humanized Col6a1-mutated knock-in mouse model of collagen VI-related muscular dystrophy
Read More
Shanghai Zheye Biotechnology divulges G12C mutant GTPase KRAS inhibitors
Read More
Peking University presents new boron-carrying agents
Read More
Cytomegalovirus DNA polymerase inhibitors discovered at the University of Alberta
Read More
New KDM1A inhibitors discovered at Shenyang Pharmaceutical University
Read More
Assessing pharmacologic activity of PD(L)-1 MAb therapeutics in tumors by target pharmacodynamics
Read More
Targeting KIR3DS1/HLA-F axis as new therapeutic strategy against human adenovirus infections
Read More
Intranasal subunit SARS-CoV-2 vaccines elicit mucosal and systemic immunity in vivo
Read More
Shionogi licenses S-365598 to ViiV for use in ultra long-acting HIV regimens
Read More
Mitochon announces funding to support development of MP-201 for TBI
Read More
RARA identified as a druggable target for pediatric acute myeloid leukemia
Read More
Point Biopharma reports preclinical data on FAP-alpha inhibitor program
Read More
SBIR grant supports Senti's development of CAR-NK cell therapy SENTI-202 for AML
Read More
Gamida Cell announces new NK cell construct development programs
Read More
Interim data on psilocybin plus NAC in rodent model of mild TBI and PTSD
Read More
LG Chem selects preclinical candidate from PD-L1/XT program with Avacta
Read More
Close SARS-CoV-2 relative strengthens natural origin theory
Read More